This fixed-dose combination of fluticasone propionate and formoterol fumarate (Flutiform inhaler) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist. Or; For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.
Flutiform 50 microgram/5 microgram is indicated in adults, adolescents and children aged 5 years and above.
Flutiform 125 microgram/5 microgram is indicated in adults and adolescents aged 12 years and above.
Flutiform 250 microgram/10 microgram inhaler is indicated in adults only.